Press Releases

Press Release

Transmission Ultrasound Pioneer Defends Intellectual Property with Darktrace AI

QT Ultrasound Deploys Enterprise Immune System for Cyber Defense
San Francisco
March 12, 2018

Darktrace, the world’s leading AI company for cyber defense, has today announced that QT Ultrasound has deployed the Enterprise Immune System to defend its intellectual property and sensitive patient information against cyber-attacks.

Safeguarding our patient data is of paramount importance,” said Casey Smith, IT Manager, QT Ultrasound. “In addition, it has taken years to develop QT Ultrasound’s technology, and an advanced cyber-attack could jeopardize our competitive advantage and undermine our reputation. With Darktrace’s AI, we can now spot the earliest signs of an emerging threat and thwart attacks before they have begun, confident in the knowledge that our critical intellectual property is secure.”

QT Ultrasound’s ground-breaking technology uses sound waves to form highly accurate images of human tissue. Having recently received clearance by the Food and Drug Administration for diagnostic imaging as an adjunct to mammograms, QT Ultrasound produces images of comparable quality to those of MRI machines. Its technology is the highest resolution, and only true 3D, transmission ultrasound technology for the early detection of breast cancer, with no uncomfortable compression and no radiation. QT Ultrasound not only needs to protect sensitive patient data, but also invaluable source code.

Modeled on the principles of the human immune system, Darktrace’s AI learns on the job about the unique ‘pattern of life’ of every user and device on an organization’s network and uses this understanding of ‘self’ to detect threatening anomalies. Unlike traditional tools, Darktrace does not rely on prior assumptions and can detect the threats others miss, including insider threat, silent and stealthy attacks, and ‘unknown unknowns’. The AI algorithms can also go a step further, autonomously stopping threats in their tracks, without interrupting business operations.

One of the defining characteristics of cyber-attacks targeting IP is their stealthy nature,” commented Rob Sass, Managing Director, North America, Darktrace. “Criminals can lurk in networks for many months and even years, unbeknownst to the security team, while they look for critical assets. Darktrace’s AI enables companies to detect even the most subtle threats, while its autonomous response capabilities allow the systems to take action against the threat. We are delighted to defend the intellectual property of tech pioneers like QT Ultrasound.”

About QT Ultrasound

QT Ultrasound is a privately held company engaged in the research, development, and commercialization of Transmission Ultrasound technology. Their research has been supported by over $15 million in funding from the National Cancer Institute of the US National Institutes of Health.  The company’s clinical trials have been conducted at many prestigious institutions in the US and Europe and it is currently enrolling women in trials at the Marin Breast Health Trial Center in Novato, California.

For more information about QT Ultrasound, visit qtultrasound.com.

For more information about the clinical trials of the QT scanner, visit marinbreasthealth.com.

About Darktrace

About Darktrace

Darktrace is the world’s leading machine learning company for cyber security. Created by mathematicians from the University of Cambridge, the Enterprise Immune System uses AI algorithms to automatically detect and take action against cyber-threats within all types of networks, including physical, cloud and virtualized networks, as well as IoT and industrial control systems. A self-configuring platform, Darktrace requires no prior set-up, identifying advanced threats in real time, including zero-days, insiders and stealthy, silent attackers. Headquartered in San Francisco and Cambridge, UK, Darktrace has 30 offices worldwide.